Objective: In this paper, we aimed to evaluate the effect and safety of intravitrealranibizumab with vitrectomy for proliferative diabetic retinopathy (PDR) patients’ treatment.
Methods: Total 26 PDR (29 eyes) patients admitted to our hospital between June 1, 2014 and January 1, 2015 were retrospectively analyzed. There were 13 cases (15 eyes) in vitrectomy (PPV) group and 13 cases in intravitrealranibizumab with vitrectomy (IVR/PPV) group. The surgery duration, electrocoagulationutilization, BCVA and complications were evaluated in the two groups.
Results: The mean surgery duration was significantly shorter in IVR/PPV group (80±15.08 min) than PPV group (108.07±11.63 min) (t=5.822, P=0.0000). The incidence of iatrogenicslit pore, vitreous hemorrhage, hyphema was significantly reduced in IVR/PPV group (P<0.05). At 6 month after operation, the visual acuity of patients were improved in both two groups and visual acuity increase of patients in IVR/PPV group was higher than PPV group (P=0.015).
Conclusion: Intravitrealranibizumab combined with vitrectomy for PDR patients’ treatment significantly reduced the surgery duration, the incidence of bleeding and complications. It may be a promising therapy for PDR patients.
Manuscripts that are Published Ahead of Print have been peer reviewed and accepted for publication by the Editorial Board of the West Indian Medical Journal. They may appear in their original format and may not be copy edited or formatted in the style guide of this Journal. While accepted manuscripts are not yet assigned a volume, issue or page numbers, they can be cited using the DOI and date of e-publication. See our Instructions for Authors on how to properly cite manuscripts at this stage. The contents of the manuscript may change before it is published in its final form. Manuscripts in this section will be removed once they have been issued to a volume and issue, but will still retain the DOI and date of e-publication.